EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
Market Closed
1 Nov, 20:00
OTC PINK OTC PINK Primary $
0. 00
-0
-99%
$
1.57K Market Cap
- P/E Ratio
- Div Yield
150 Volume
0 Eps
$ 0
Previous Close Want to track EPRSQ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
EPRSQ closed Wednesday lower at $0, a decrease of -99% from Tuesday's close, completing a monthly increase of 0% or $0. Over the past 12 months, EPRSQ stock gained 0%.
EPRSQ is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
EPIRUS Biopharmaceuticals, Inc. has completed 2 stock splits, with the recent split occurring on Jul 16, 2014.
The company's stock is traded on one exchange.
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
EPIRUS Biopharmaceuticals, Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is EPRSQ.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.57K.
Has EPIRUS Biopharmaceuticals, Inc. ever had a stock split?
EPIRUS Biopharmaceuticals, Inc. had 2 splits and the recent split was on Jul 16, 2014.
EPIRUS Biopharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jeff Kagy CEO | OTC PINK Exchange | 29428P107 CUSIP |
| US Country | 73 Employees | - Last Dividend | 3 Oct 2013 Last Split | - IPO Date |
Overview
EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company focused on the development, manufacturing, and commercialization of biosimilar therapeutics globally. Founded in 2011 and based in Boston, Massachusetts, the company aimed to address the growing need for accessible biosimilar treatments for various inflammatory diseases. Despite its promising product pipeline and strategic partnerships with entities like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A., Epirus Biopharmaceuticals filed for liquidation under Chapter 7 on July 25, 2016, in the US Bankruptcy Court for the District of Massachusetts, marking an end to its operations.
Products and Services
- BOW015 - A biosimilar version of Remicade (infliximab), aimed at treating a variety of inflammatory diseases. This lead product candidate was positioned to offer an alternative, potentially more affordable treatment option for patients suffering from chronic inflammatory conditions.
- BOW050 - A biosimilar version of Humira (adalimumab) designed to treat inflammatory diseases such as rheumatoid arthritis, various forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW050 was part of EPIRUS's ambition to expand its portfolio in the highly lucrative market of biosimilars for autoimmune diseases.
- BOW070 - A biosimilar of Actemra (tocilizumab) that was under development for the treatment of conditions like rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. This product candidate highlighted the company's efforts to diversify its biosimilar offerings across different therapeutic areas.
- BOW080 - A biosimilar version of Soliris aimed at treating ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This product underscored the company’s commitment to addressing unmet medical needs in niche markets.
- BOW100 - A biosimilar version of SIMPONI geared towards the treatment of inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. BOW100 was part of the company's strategy to offer a broad range of treatment options for autoimmune disorders.
Contact Information
Address: 699 Boylston Street
Phone: 617-600-3497
Website: https://epirusbiopharma.com
